Cinacalcet, a positive allosteric modulator of CaSR, can decrease PTH secretion(6) and was successfully used for FHH with a more severe hypercalcemia(7,8), however its benefits in mild presentation of FHH is counterbalanced by possible side effects (hypocalcemia, nausea, vomiting) and cost burden (9,10). Here, CASR is linked to Hypercalcemia.